Torvutatug samrotecan clinical trials
Also written AZD5335.
How each study uses torvutatug samrotecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the torvutatug samrotecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test torvutatug samrotecan.
Studies
Open first, then newest update. How each study uses torvutatug samrotecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian CancerRecruitingPhase 3AstraZenecaNCT07851025Written as Torvutatug samrotecan
- Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian CancerRecruitingPhase 3AstraZenecaNCT07816666Written as Torvutatug samrotecan
- Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsRecruitingPhase 1/2AstraZenecaNCT05797168Written as Torvutatug samrotecan
- Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecruitingPhase 1AstraZenecaNCT07402915Written as AZD5335
- AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerRecruitingPhase 3AstraZenecaNCT07218809Written as AZD5335
Codes
What other systems call torvutatug samrotecan · ClinicalTrials.gg INT016418
- UNII (FDA) E5QZ8ZF3HETORVUTATUG SAMROTECANOne source FDA
- NCI Thesaurus C200057Torvutatug SamrotecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | E5QZ8ZF3HE | TORVUTATUG SAMROTECAN | One source FDA |
| NCI Thesaurus | C200057 | Torvutatug Samrotecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.